##### 



Exhibit
10.53   ***Text Omitted and Filed SeparatelyConfidential Treatment
RequestedUnder 17 C.F.R. §§ 200.80(b)(4)
and240.24b-2(b)(1)
 SERVICES AGREEMENT
 THIS SERVICES AGREEMENT Agreement Effective
Date Pharmexa IDM Party Parties
 WITNESSETH
 WHEREAS, Asset Purchase Agreement
 WHEREAS,
 WHEREAS, ® EIS EIS License
Agreement
 WHEREAS,
 NOW, THEREFORE,
 1. DEFINITIONS.
 1.1 Affiliate
 1.2 Antigen
 1.3 Applicable Law
 1.4 Confidential Information
 1




---



##### 



1.5 Consumables Exhibit B
 1.6 FTE
 1.7 IDM Supplies
 1.8 Indemnitee
 1.9 Indemnitor
 1.10 Patents
 1.11 Project Data
 1.12 Project Managers
 1.13 Research Labs
 1.14 Services Exhibit A
 1.15 Task Order
 1.16 Term
 2. RESEARCH LABS.
 2.1 Covenant by Pharmexa.
 *
    
    Confidential TreatmentRequested
Under 17 C.F.R. §§200.80(b)(4) AND 240.24b-2(b)(1)
 2




---



##### 



2.2 Notice of Closure. Exhibit C
 3. PERFORMANCE OF SERVICES.
 3.1 Project Managers. Project Managers
 3.2 Steering Committee. Steering Committee Quarterly Meeting Projected Resource Requirements
 3.3 Task Orders.
 *
    
    Confidential TreatmentRequested
Under 17 C.F.R. §§200.80(b)(4) AND 240.24b-2(b)(1)
 3




---



##### 



.
 3.4 Scope.
 3.5 Proprietary Supplies. IDM Supplies
 *
    
    Confidential TreatmentRequested
Under 17 C.F.R. §§200.80(b)(4) AND 240.24b-2(b)(1)
 4




---



##### 



3.6 Reports of Results. Project Data
 3.7 Modification of Task Orders.
 3.8 Quality Control.
 4. PAYMENT.
 4.1 Research Fees.
 *
    
    Confidential TreatmentRequested
Under 17 C.F.R. §§200.80(b)(4) AND 240.24b-2(b)(1)
 5




---



##### 



Peptide
Synthesis Cost Exhibit A
 4.2 Initial Credit.
 4.3 Records; Audit.
 *
    
    Confidential TreatmentRequested
Under 17 C.F.R. §§200.80(b)(4) AND 240.24b-2(b)(1)
 6




---



##### 



5. TERM AND TERMINATION
 5.1 Term.
 5.2 Termination by IDM.
 5.3 Termination by Pharmexa
 5.4 Termination of Agreement for Material Breach
 5.5 Survival.
 *
    
    Confidential TreatmentRequested
Under 17 C.F.R. §§200.80(b)(4) AND 240.24b-2(b)(1)
 7




---



##### 



6. INSPECTIONS.
 6.1 Regulatory Inspections.
 6.2 Site Visits by IDM.
 7. OWNERSHIP.
 7.1 Disclosure of Project Inventions. Project Invention
 7.2 IDM Inventions. IDM Project Inventions
 8




---



##### 



7.3 Project Data.
 8. CONFIDENTIALITY.
 8.1 Confidential Information.
 8.2 Exceptions to Confidential Information.
 8.3 Disclosure Required by Law.
 *
    
    Confidential TreatmentRequested
Under 17 C.F.R. §§200.80(b)(4) AND 240.24b-2(b)(1)
 9




---



##### 



8.4 Return of Confidential Information.
 8.5 Injunctive Relief.
 8.6 Disclosure of Agreement.
 9. REPRESENTATIONS AND WARRANTIES.
 9.1 General Representations.
 (a) Authority.
 10




---



##### 



(b) Due Execution.
 (c) No Third Party Approval.
 (d) Binding Agreement.
 9.2 No Infringement.
 9.3 Disclaimers.
 10. INSURANCE.
  11. INDEMNIFICATION AND LIMITATION OF LIABILITY.
 11.1 Indemnification by IDM. Pharmexa
Indemnitee Losses
 11




---



##### 



11.2 Indemnification by Pharmexa. IDM Indemnitee
 11.3 Certain Procedures Regarding Indemnification.
 (a) Claim Claim Notice
 (b)
 *
    
    Confidential TreatmentRequested
Under 17 C.F.R. §§200.80(b)(4) AND 240.24b-2(b)(1)
 12




---



##### 



(c)
 11.4 Limitation of Liability.
 11.5 Resolution of Disputed Indemnification Claim. Contested Claim
 12. MISCELLANEOUS.
 12.1 Arbitration.
 (a) Dispute
 (i)
 *
    
    Confidential TreatmentRequested
Under 17 C.F.R. §§200.80(b)(4) AND 240.24b-2(b)(1)
 13




---



##### 



(ii)
 (iii)
 (iv)
 (v)
 (b)
 (c)
 12.2 Assignment.
 14




---



##### 



12.3 Relationship of Parties.
 12.4 Entire Agreement; Amendment.
 12.5 Severability.
 12.6 Non-Waiver.
 12.7 Governing Law.
 12.8 Force Majeure.
 15




---



##### 



12.9 Notices.
 If
to IDM:
    

If
to Pharmexa:IDM Pharma, Inc.
    
    Pharmexa Inc.9 Parker, Suite 100
    
    5820 Nancy Ridge DriveIrvine, CA 92618-1605
    
    San Diego, CA 92121USA
    
    USAAttn:___
    
    Attn: Chief Executive OfficerWith a copy to:
    
    With copies to:Pharmexa A/SCooley Godward LLP
    
    Kogle Allé 64401 Eastgate Mall
    
    DK-2970 HørsholmSan Diego, CA 92121-1909
    
    DenmarkUSA
    
    Attn: Chief Financial OfficerAttn: ___andNordlicht & Hand645 Fifth AvenueNew York, NY 10022USAAttn: Brian M. Hand, Esq.
 12.10 Counterparts.
 12.11 No Implied Rights or License.
 16




---



##### 



12.12 Article and Section Headings and Gender.
 12.13 Exhibits.
 12.14 Public Announcements.
 12.15 Office Space
 *
    
    Confidential TreatmentRequested
Under 17 C.F.R. §§200.80(b)(4) AND 240.24b-2(b)(1)
 17




---



##### 



12.16 Clinical Trial Employee
 12.17 Training
  *
    
    Confidential TreatmentRequested
Under 17 C.F.R. §§200.80(b)(4) AND 240.24b-2(b)(1)
 18




---



##### 



IN WITNESS WHEREOF
 PHARMEXA INC.
    
    
    
    IDM PHARMA, INC.By:
 /s/ Marc Hertz





     
    
    

By:
 /s/ Robert De VaereName:
    
    Marc Hertz
    
    
    
    Name:
    
    Robert De VaereTitle:
    
    CEO
    
    
    
    Title:
    
    Chief Financial Officer
 19




---



##### 



Exhibit A
Description of Services
  
 *

    Presumes that all listed equipment has been transferred to Pharmexa in connection with
the consummation of the transactions contemplated by the Asset Purchase Agreement. *
    
    Confidential TreatmentRequested
Under 17 C.F.R. §§200.80(b)(4) AND 240.24b-2(b)(1)




---



##### 



*

    Presumes that all listed equipment has been transferred to Pharmexa in connection with
the consummation of the transactions contemplated by the Asset Purchase Agreement. *
    
    Confidential TreatmentRequested
Under 17 C.F.R. §§200.80(b)(4) AND 240.24b-2(b)(1)




---



##### 



Exhibit B
Consumables
  *
    
    Confidential TreatmentRequested
Under 17 C.F.R. §§200.80(b)(4) AND 240.24b-2(b)(1)




---



##### 



*
    
    Confidential TreatmentRequested
Under 17 C.F.R. §§200.80(b)(4) AND 240.24b-2(b)(1)




---



##### 



Exhibit C
Training Rates
   *
    
    Confidential TreatmentRequested
Under 17 C.F.R. §§200.80(b)(4) AND 240.24b-2(b)(1)




---



##### 



Exhibit D
Plasman Services
  *
    
    Confidential TreatmentRequested
Under 17 C.F.R. §§200.80(b)(4) AND 240.24b-2(b)(1)